Market Overview

According to Metastat Insight-style structured analysis, the global drug-eluting stents market is valued at USD 6,355.6 million in 2025 and is projected to grow at a CAGR of 8.4% from 2025 to 2032, potentially exceeding USD 11,182.3 million.
The market has evolved from the 1990s era of bare-metal stents to modern polymer-coated devices that significantly reduce restenosis rates. Today, these medical solutions are critical for treating coronary and peripheral artery diseases, driven by engineering innovations and a global transition toward minimally invasive cardiovascular procedures.

Major Players Profiled in the Market Report:

• Abbott Laboratories
• Boston Scientific Corporation
• Terumo Corporation
• Medtronic plc
• Biosensors International
• Cook Medical
• B. Braun
• Biotronik
• Lepu Medical Technology
• OrbusNeich Medical Company Limited
• Shanghai MicroPort Medical Co., Ltd.
• Sino Medical Sciences Technology Inc.
• Eurocor GmbH

Segments

Technology Differentiation

By Coating Type, the market is segmented into Polymer-based and Polymer-free coatings. Polymer-based Coatings dominate the market with a 77.8% share, favored for controlled drug release. Polymer-free Coatings are gaining traction by reducing inflammation risks and utilizing surface design for medication delivery.

Material and Application Diversity

By Material, the market includes Metal, Stainless-Steel, Cobalt-Chromium, and Nitinol. Cobalt-chromium is noted for its thin structure and visibility, while Nitinol is valued for shape-memory flexibility. By Application, the market serves Coronary Artery Disease and Peripheral Artery Disease, with Hospitals remaining the primary end-user.

Source: https://www.metastatinsight.com/report/drug-eluting-stents-market

Report Coverage

The report offers:
• Full in-depth analysis of the cardiovascular device parent industry
• Detailed segmentation by coating type, material, application, and end-user
• Historical, ongoing, and projected market analysis (2025–2032)
• Key strategies of major players and regional growth potential

Drivers & Restraints

Drivers

The primary drivers include the rising global prevalence of cardiovascular diseases and technological advancements in nanotechnology and drug-polymer science that improve long-term safety and efficacy.

Restraints

High initial costs compared to bare-metal stents and clinical concerns regarding late stent thrombosis, which necessitates prolonged antiplatelet therapy, act as significant market barriers.

Regional Insights

North America remains a pivotal hub driven by high healthcare expenditure in the U.S. Europe and Japan maintain rigorous regulatory standards for biocompatibility, while Asia-Pacific (led by China and India) is a major growth hub due to expanding catheterization laboratory capacities.

Competitive Landscape

Leaders like Abbott, Boston Scientific, and Medtronic are focusing on next-generation biodegradable and polymer-free technologies to mimic natural blood vessel behavior and enhance clinical outcomes.